{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:33Z","timestamp":1789387593746,"version":"build-2803163510"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec id=\"ab-coi250047-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>\n                      Most patients with clinically node-positive (cN\n                      <jats:sup>+<\/jats:sup>\n                      ) breast cancer receive primary systemic treatment (PST) followed by axillary lymph node dissection (ALND) and\/or locoregional radiation (RT). The necessity of axillary treatment in patients achieving nodal pathologic complete response (pCR) after PST remains uncertain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250047-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess oncologic outcomes of response-guided axillary treatment determined by marking the axillary lymph node with a radioactive iodine seed (MARI) in patients with cN\n                      <jats:sup>+<\/jats:sup>\n                      breast cancer who experience pCR after PST.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250047-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study was conducted at a single center including patients with breast cancer with 3 or fewer axillary lymph nodes on fluorodeoxyglucose positron emission tomography\u2212computed tomography who were treated according to the MARI protocol from July 2014 to December 2021. Patients with intramammary or periclavicular lymph node involvement were excluded. Median (IQR) follow-up was 49 (32-70) months. Data were analyzed from March to June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250047-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>\n                      After PST, the MARI-marked lymph node was excised. Patients with  pCR of the MARI node (ypN0) received no further axillary treatment, whereas patients with residual disease (ypN\n                      <jats:sup>+<\/jats:sup>\n                      ) received locoregional radiation therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250047-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome measure was axillary recurrence rate. The secondary outcome measures were 5-year invasive disease-free survival (iDFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250047-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 350 patients (median [IQR] age, 49 [41-56] years) were included and analyzed; of these, 135 (39%) had ypN0 and received no further axillary treatment. The remaining 215 patients with ypN\n                      <jats:sup>+<\/jats:sup>\n                      (61%) received RT. After a median (IQR) follow-up of 49 (32-70) months, axillary recurrence rate was 0.7% (n\u2009=\u20091; 95% CI, 0.04%-4.1%) in patients with ypN0 and 2.3% (n\u2009=\u20097; 95% CI, 1.0%-5.3%) in patients with ypN\n                      <jats:sup>+<\/jats:sup>\n                      . In patients with ypN0, the 5-year iDFS was 93% (95% CI, 88%-98%) and the OS was 98% (95% CI, 95%-100%); in patients with ypN\n                      <jats:sup>+<\/jats:sup>\n                      , iDFS was 87% (95% CI, 82%-93%) and OS, 93% (95% CI, 89%-97%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-coi250047-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cohort study found that response-guided axillary treatment, using the MARI protocol, in patients with limited nodal disease who received PST was associated with a very low risk of axillary recurrence and should be considered to protect patients from axillary overtreatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2752","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:31:08Z","timestamp":1756395068000},"page":"1204","source":"Crossref","is-referenced-by-count":13,"title":["Iodine Seed\u2212Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Annemiek K. E.","family":"van Hemert","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane A.","family":"van Loevezijn","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Sophie P. D.","family":"Baas","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P. M.","family":"Stokkel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Groen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudette E.","family":"Loo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke H.","family":"van Duijnhoven","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jeanne T. F. D.","family":"Vrancken Peeters","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute\u2013Antoni van Leeuwenhoek, Amsterdam, the Netherlands"},{"name":"Department of Surgery, University Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi250047r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis.","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"25","key":"coi250047r2","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250047r3","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"9816","key":"coi250047r4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"coi250047r5","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10257","key":"coi250047r6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"9938","key":"coi250047r7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"coi250047r8","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250047r9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","article-title":"Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy.","volume":"2","author":"Mougalian","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"coi250047r10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"coi250047r11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2023.06.011","article-title":"This house believes that: MARI\/TAD is better than sentinel node biopsy after PST for cN+ patients.","volume":"71","author":"van Hemert","year":"2023","journal-title":"Breast"},{"issue":"2","key":"coi250047r12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"2","key":"coi250047r13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamasurg.2014.1086","article-title":"Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.","volume":"150","author":"Caudle","year":"2015","journal-title":"JAMA Surg"},{"issue":"12","key":"coi250047r14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event.","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"coi250047r15","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer.","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"coi250047r16","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer.","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"coi250047r17","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1097\/SLA.0000000000004562","article-title":"Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy: long-term results of a prospective interventional study.","volume":"276","author":"Martelli","year":"2022","journal-title":"Ann Surg"},{"issue":"2","key":"coi250047r18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-020-06011-8","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.","volume":"186","author":"Damin","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"coi250047r19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"coi250047r20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4048\/jbc.2021.24.e48","article-title":"Sentinel lymph node biopsy in breast cancer patients with pathological complete response in the axillary lymph node after neoadjuvant chemotherapy.","volume":"24","author":"Kim","year":"2021","journal-title":"J Breast Cancer"},{"issue":"3","key":"coi250047r21","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae071","article-title":"Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement.","volume":"111","author":"de Wild","year":"2024","journal-title":"Br J Surg"},{"issue":"1","key":"coi250047r22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jso.27241","article-title":"Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center.","volume":"128","author":"Sargent","year":"2023","journal-title":"J Surg Oncol"},{"issue":"10","key":"coi250047r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.05.013","article-title":"Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.","volume":"49","author":"Siso","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"coi250047r24","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/JS9.0000000000000331","article-title":"Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.","volume":"109","author":"Wu","year":"2023","journal-title":"Int J Surg"},{"issue":"6","key":"coi250047r25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","article-title":"Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy.","volume":"10","author":"Montagna","year":"2024","journal-title":"JAMA Oncol"},{"issue":"12","key":"coi250047r26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi250047r27","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial.","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250047r28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"issue":"9","key":"coi250047r30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/bjs.10555","article-title":"Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.","volume":"104","author":"Koolen","year":"2017","journal-title":"Br J Surg"},{"issue":"1","key":"coi250047r31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.radonc.2015.12.027","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1.","volume":"118","author":"Offersen","year":"2016","journal-title":"Radiother Oncol"},{"issue":"7","key":"coi250047r32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"coi250047r33","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"coi250047r34","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1093\/annonc\/mdv478","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"coi250047r35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-023-07062-3","article-title":"Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy.","volume":"202","author":"Dux","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"coi250047r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108472","article-title":"Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy: a two center cohort study.","volume":"50","author":"Schipper","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"coi250047r37","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3159641\/v1","article-title":"Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study.","author":"de Wild","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"coi250047r38","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1245\/s10434-024-15182-3","article-title":"Implementation of the targeted axillary dissection procedure in clinically node-positive breast cancer: a retrospective analysis.","volume":"31","author":"Nijveldt","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"coi250047r40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaoncol.2024.1136","article-title":"Axillary surgery for chemoresidual (ypN-Positive) nodal disease.","volume":"10","author":"Brooks","year":"2024","journal-title":"JAMA Oncol"},{"issue":"11","key":"coi250047r41","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma.","volume":"56","author":"Hogan","year":"2015","journal-title":"J Nucl Med"},{"issue":"3","key":"coi250047r42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.120.247882","article-title":"Head-to-head evaluation of 18F-FES and 18F-FDG PET\/CT in metastatic invasive lobular breast cancer.","volume":"62","author":"Ulaner","year":"2021","journal-title":"J Nucl Med"},{"issue":"9","key":"coi250047r43","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S1470-2045(24)00350-4","article-title":"Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4\/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.","volume":"25","author":"de Boniface","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi250047r44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1245\/s10434-023-14404-4","article-title":"Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101).","volume":"31","author":"Weber","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"524","key":"coi250047r46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.524","article-title":"Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.","volume":"16","author":"Vega","year":"2023","journal-title":"J Clin Oncol"},{"key":"coi250047r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103806","article-title":"Role of [18F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: literature review and comparison between guidelines.","volume":"78","author":"Groheux","year":"2024","journal-title":"Breast"},{"issue":"32","key":"coi250047r48","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.","volume":"30","author":"Mamounas","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250047r49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/bjs.11963","article-title":"Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.","volume":"108","author":"Zetterlund","year":"2021","journal-title":"Br J Surg"},{"issue":"4","key":"coi250047r50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB).","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"issue":"1","key":"coi250047r51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-023-00525-2","article-title":"Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.","volume":"9","author":"Huober","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"coi250047r52","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00259-021-05502-0","article-title":"Comparison of nodal staging between CT, MRI, and [18F]-FDG PET\/MRI in patients with newly diagnosed breast cancer.","volume":"49","author":"Morawitz","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"coi250047r53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260804","article-title":"Prospective comparison of CT and 18F-FDG PET\/MRI in N and M staging of primary breast cancer patients: Initial results.","volume":"16","author":"Bruckmann","year":"2021","journal-title":"PLoS One"},{"key":"coi250047r29","unstructured":"Alliance for Clinical Trials in Oncology. Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy (ALLIANCE A011202). Accessed July 24, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094"},{"key":"coi250047r39","doi-asserted-by":"crossref","unstructured":"Mamounas? E, Bandos? H, White? J,  Abstract GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy. Cancer Research. 2024;84:GS02-07. doi:10.1158\/1538-7445.SABCS23-GS02-07","DOI":"10.1158\/1538-7445.SABCS23-GS02-07"},{"key":"coi250047r45","unstructured":"European Breast Cancer Research Association of Surgical Trialists. Axillary Surgery After NeoAdjuvant Treatment. AXSANA. 2023. Accessed September 20, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04373655"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2838070\/jamaoncology_van_hemert_2025_oi_250047_1765403580.08286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:00:41Z","timestamp":1765468841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2838070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2752","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}